Cardiac Safety of Liposomal Anthracyclines

Cardiac Safety of Liposomal Anthracyclines Tamar Safra Oncologist 2003; 8(Suppl 2): 17-24 Author Information and Disclosures Target Audience: Physicians who wish to advance their current knowledge of clinical cancer medicine in breast cancer and are involved in providing patient care in a cancer care environment. Method of Physician Participation: Read course materials, complete course quiz and evaluation form (optional). Learning Objectives After completing this course, the reader should be able to: Describe the cardiac toxicity profiles of conventional anthracyclines. Discuss the published data evaluating the cardiac safety of liposomal anthracyclines. Describe MUGA scan monitoring recommendations for patients treated with liposomal anthracyclines. The NIH/FAES designates this educational activity for a maximum of 1 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity. Click Here to return to the complete course listing of Liposomal Anthracyclines for Breast Cancer: Clinical Efficacy and Safety Update.

CME Activity Information Accreditation CME Instructions For Credit Privacy Statement Hardware/Software Requirements Release Date: Sept. 18, 2003 Most Recent Review: June 10, 2005* Most Recent Update: Sept. 18, 2003 Date Credit Expires: Apr. 10, 2007 Time to Complete: 1 hour Medium: Internet Online *Click here to learn more about our review process.